Advances in Gastric and GE Junction Cancer Treatment: Durvalumab Combined with FLOT Shows Promising Results at ASCO
A groundbreaking phase 3 trial shows that combining durvalumab with FLOT chemotherapy significantly improves outcomes for patients with resectable gastric and GE junction cancer, offering new hope in cancer treatment.
Recent research presented at the American Society of Clinical Oncology (ASCO) meeting highlights a significant breakthrough in the treatment of resectable gastric and gastroesophageal (GE) junction adenocarcinoma. A phase 3, double-blind clinical trial investigated the efficacy of adding durvalumab, an immunotherapy drug, to the standard FLOT chemotherapy regimen.
The study involved 948 patients who were randomly assigned to receive either durvalumab (1,500 mg) or a placebo every four weeks. The treatment plan included four cycles of the combined therapy followed by 10 additional cycles of durvalumab or placebo. The primary focus was to assess event-free survival, which measures the length of time patients remain free from disease progression or recurrence.
Findings demonstrated that patients receiving durvalumab experienced notably better outcomes. The two-year event-free survival rate was 67.4% in the durvalumab group compared to 58.5% in the placebo group. Overall survival also improved, with 75.7% of durvalumab-treated patients surviving at two years versus 70.4% in the control group. Additionally, a higher proportion of patients in the durvalumab group achieved a pathological complete response (19.2% vs. 7.2%), indicating an absence of detectable cancer after treatment.
Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center emphasized the importance of these findings, stating that this therapy combination could represent a major advancement for patients facing this challenging diagnosis. The results suggest that adding durvalumab to the FLOT regimen could significantly enhance patient outcomes, bringing hope for higher cure rates.
The study was sponsored by AstraZeneca, which manufactures durvalumab. Several authors disclosed ties to pharmaceutical companies, aligned with the industry-led nature of the research.
For more on this study, visit the published article in the New England Journal of Medicine and the ASCO annual meeting resources.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Early Mitochondrial Dysfunction and Myelin Loss Key Factors in Multiple Sclerosis Brain Damage
New research sheds light on how early mitochondrial impairment and myelin loss contribute to cerebellar damage in multiple sclerosis, offering hope for targeted therapies to protect brain health.
First Clinical Trial Launches for Therapeutic Hepatitis B Vaccine
A groundbreaking therapeutic vaccine for chronic hepatitis B has entered human clinical trials, promising a potential new treatment to cure the disease and improve global health outcomes. Developed by researchers at the Technical University Munich, TherVacB aims to activate the immune system and target multiple strains of the virus.
Potential of Weight Loss Interventions to Reduce Obesity-Related Cancer Risks in Diabetic Patients
Weight loss treatments, including medication and surgery, may lower the risk of obesity-related cancers in people with diabetes, according to recent research. A large study from the University of Leicester highlights the cancer-reducing potential of therapies like semaglutide and bariatric surgery.
Cost-Effective Strategies to Manage Food Allergies at Summer Camps
A recent UVA study explores affordable and effective strategies for managing food allergies at summer camps, emphasizing stock epinephrine to protect children from life-threatening reactions.